DAYBU recommended for approval in the European Union
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Neuren Pharmaceuticals Limited has announced that DAYBU® (trofinetide) has been recommended for approval in the European Union by the Committee for Medicinal Products for Human Use following a re-examination procedure. If approved, DAYBU® would be the first treatment for neurobehavioral symptoms of Rett syndrome in the EU, and Neuren would receive significant financial benefits upon its commercial sale. Neuren's CEO expressed delight at this positive outcome, emphasizing the importance of this potential treatment for patients and caregivers affected by Rett syndrome. The European Commission is expected to issue a final decision on the marketing authorisation in the coming months.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Q1 2026 DAYBUE net sales US$101m, up 20% from Q1 2025
- DAYBUE STIX now broadly available in US for Rett syndrome
- Acadia confirms plan to request CHMP re-examination
- 2025 royalty income A$65m, profit after tax A$30m
- Appendix 4E and 2025 full year accounts
Later from Neuren Pharmaceuticals
- Record Q2 DAYBUE net sales of US$125m, CY26 royalty upgraded
- Neuren H1 2026 Financial Results Webinar on 26 August 2026
- European Commission grants marketing authorisation for DAYBU
- Half Yearly Report and Accounts
- Growing royalty anchors Neuren first ever dividend program
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals